Research
Search
Close
LUO Yanli
- Graduate Supervisor, Associate Professor
- Department: Pathology
- Research Area: Clinical Pathology
- Research Interests: Pathogenesis of bone tumor
- Contact: luoyanli2000@163.com
- MD from Shanghai Jiao Tong University School of Medicine, 2012
- PhD from Xinxiang Medical University,2007
- MPH from Xinxiang Medical University, 2004
- Yanli Luo*, Juan Tang, Jin Huang, Dingjun Hu,Yueqing Bai, Jie Chen, Keyang Sun, Huizhen Zhang,Zhiyan Liu.Diagnostic value of H3F3A mutation and clinicopathological features of giant cell tumours in non-long bones, J Bone Oncol, 2022. doi: 10.1016/j.jbo.2022.100467.
- Qianqian Zhao, Juan Tang,Yanli Luo*,Jin Huang, Dingjun Hu, Jinyu Zhu,Ting Jiang, Huizhen Zhang, Zhiyan Liu .Chondroblastoma: clinicopathological analyses of 307 cases from a single institution in China and the diagnostic value of the H3F3 K36M mutant antibody,J Clin Pathol. 2023. doi: 10.1136/jcp-2022-208630.
- Yanli Luo,Junqing Yuan, Jin Huang,Tingting Yang, Jun Zhou, Juan Tang, Min Liu,Jie Chen,Wentao Huang, Huizhen Zhang. Role of PRPS2 as a prognostic and therapeutic target in osteosarcoma, J Clin Pathol. 2021. doi: 10.1136/jclinpath-2020-206505.
- Tingting Yang,Yueqing Bai,Jie Chen, Keyang Sun,Yanli Luo#,Wentao Huang,Huizhen Zhang. Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin, J Bone Oncol. 2020. doi: 10.1016/j.jbo.2020.100293.
- Yanli Luo#,Wentao Huang, Huizhen Zhang,Guang Liu .Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer,Oncol Lett. 2018 . doi: 10.3892/ol.2018.8104.
- 01/01/2016-12/31/2019
National Natural Science Foundation of China，youth project，¥170000, 81602099
The Mechanism of L1CAM Promoting Reproducibility of pancreatic cancer after Radiotherapy via CyclinD1 Dependent Pathway.
Role: Project leader - 01/01/2015-12/31/2018
Shanghai Jiao Tong University Medical and Industrial Cross disciplinary Youth Project，¥120000,YG2015QN12
Construction nanocarriers releasing control of siRNA delivery and their preliminary application in the model of post radiotherapy tolerance of pancreatic cancer.
Role: Project leader
